BioWorld

March 27, 2002

ISTA’s Stock Slides On Vitrase Missed Primary Endpoint

Wall Street did not look kindly on ISTA Pharmaceuticals’ failure to meet its primary endpoint in two pivotal Phase III studies of Vitrase, a single injection for treating vitreous hemorrhage. (BioWorld Today) Read More

AVI Financing Garners $22M For Antisense, Cancer Vaccines

Huntington’s Disease Divulges Perplexities Of Its Horrendous Hallmarks, Inexorable Lethality

TKT’s Dynepo Gains Approval In Europe; Amgen Fight Goes On

Bush Unveils Planned NIH, Surgeon General Nominations

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan. 17, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for January 17, 2025

Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal

BioWorld

The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...

Proteomics study explores how protein changes influence disease

BioWorld Science

Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...

Illustration of cell receptors, antibodies

Abbvie and Simcere enter a $1B T-cell engager deal

BioWorld Asia

Abbvie Inc. and Simcere Zaiming Pharmaceutical Co. Ltd. are part of the volley of large deals accompanying the opening of the 43rd annual J.P. Morgan Healthcare...